168 related articles for article (PubMed ID: 24858806)
1. Low blood levels of sTWEAK are related to locoregional failure in head and neck cancer.
Avilés-Jurado FX; Terra X; Gómez D; Flores JC; Raventós A; Maymó-Masip E; León X; Serrano-Gonzalvo V; Vendrell J; Figuerola E; Chacón MR
Eur Arch Otorhinolaryngol; 2015 Jul; 272(7):1733-41. PubMed ID: 24858806
[TBL] [Abstract][Full Text] [Related]
2. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis.
Kowal-Bielecka O; Bielecki M; Guiducci S; Trzcinska-Butkiewicz B; Michalska-Jakubus M; Matucci-Cerinic M; Brzosko M; Krasowska D; Chyczewski L; Kowal K
Arthritis Res Ther; 2013; 15(3):R69. PubMed ID: 23800379
[TBL] [Abstract][Full Text] [Related]
3. Role of the tumour necrosis factor-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) axis in autoimmune thyroid disease.
Peng S; Yu X; Zhao X; Wang X; Sun X; Han C; Shan Z; Li C; Teng W
Clin Endocrinol (Oxf); 2017 Dec; 87(6):783-790. PubMed ID: 28636775
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: relationship with cardiovascular risk factors. a case-control study.
Llauradó G; González-Clemente JM; Maymó-Masip E; Subías D; Vendrell J; Chacón MR
PLoS One; 2012; 7(8):e43919. PubMed ID: 22937125
[TBL] [Abstract][Full Text] [Related]
5. Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure.
Ptaszynska-Kopczynska K; Marcinkiewicz-Siemion M; Lisowska A; Waszkiewicz E; Witkowski M; Jasiewicz M; Miklasz P; Jakim P; Galar B; Musial WJ; Kaminski KA
Cytokine; 2016 Apr; 80():7-12. PubMed ID: 26916171
[TBL] [Abstract][Full Text] [Related]
6. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio.
Moreno JA; Dejouvencel T; Labreuche J; Smadja DM; Dussiot M; Martin-Ventura JL; Egido J; Gaussem P; Emmerich J; Michel JB; Blanco-Colio LM; Meilhac O
Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1253-62. PubMed ID: 20299688
[TBL] [Abstract][Full Text] [Related]
7. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease.
Urbonaviciene G; Martin-Ventura JL; Lindholt JS; Urbonavicius S; Moreno JA; Egido J; Blanco-Colio LM
Atherosclerosis; 2011 Dec; 219(2):892-9. PubMed ID: 21962403
[TBL] [Abstract][Full Text] [Related]
8. External validation of sTWEAK as a prognostic noninvasive biomarker for head and neck squamous cell carcinoma.
Terra X; Gómez D; García-Lorenzo J; Flores JC; Figuerola E; Mora J; Chacón MR; Quer M; Camacho M; León X; Avilés-Jurado FX
Head Neck; 2016 Apr; 38 Suppl 1():E1358-63. PubMed ID: 26676381
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension.
Jasiewicz M; Kowal K; Kowal-Bielecka O; Knapp M; Skiepko R; Bodzenta-Lukaszyk A; Sobkowicz B; Musial WJ; Kaminski KA
Cytokine; 2014 Mar; 66(1):40-5. PubMed ID: 24548423
[TBL] [Abstract][Full Text] [Related]
10. The association of high sCD163/sTWEAK ratio with cardiovascular disease in hemodialysis patients.
Rusu CC; Racasan S; Kacso IM; Ghervan L; Moldovan D; Potra A; Patiu IM; Bondor C; Caprioara MG
Int Urol Nephrol; 2015 Dec; 47(12):2023-30. PubMed ID: 26433887
[TBL] [Abstract][Full Text] [Related]
11. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease.
Valdivielso JM; Coll B; Martín-Ventura JL; Moreno JA; Egido J; Fernández E; Blanco-Colio LM
J Nephrol; 2013; 26(6):1105-13. PubMed ID: 23475462
[TBL] [Abstract][Full Text] [Related]
12. Serum sCD163 levels are associated with type 2 diabetes mellitus and are influenced by coffee and wine consumption: results of the Di@bet.es study.
Rojo-Martínez G; Maymó-Masip E; Rodríguez MM; Solano E; Goday A; Soriguer F; Valdés S; Chaves FJ; Delgado E; Colomo N; Hernández P; Vendrell J; Chacón MR
PLoS One; 2014; 9(6):e101250. PubMed ID: 24978196
[TBL] [Abstract][Full Text] [Related]
13. Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.
Beltrán LM; Muñoz Hernández R; de Pablo Bernal RS; García Morillo JS; Egido J; Noval ML; Ferrando-Martinez S; Blanco-Colio LM; Genebat M; Villar JR; Moreno-Luna R; Moreno JA
PLoS One; 2014; 9(3):e90541. PubMed ID: 24594990
[TBL] [Abstract][Full Text] [Related]
14. Inter- not intraindividual differences in sTWEAK levels predict functional deterioration and mortality in patients with dilated cardiomyopathy.
Jarr KU; Nelles M; Katus HA; Chorianopoulos E
Mediators Inflamm; 2014; 2014():576482. PubMed ID: 25089077
[TBL] [Abstract][Full Text] [Related]
15. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis.
Moreno JA; Muñoz-García B; Martín-Ventura JL; Madrigal-Matute J; Orbe J; Páramo JA; Ortega L; Egido J; Blanco-Colio LM
Atherosclerosis; 2009 Nov; 207(1):103-10. PubMed ID: 19473660
[TBL] [Abstract][Full Text] [Related]
16. HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels.
López-Dupla M; Maymó-Masip E; Martínez E; Domingo P; Leal M; Peraire J; Viladés C; Veloso S; Arnedo M; Ferrando-Martínez S; Beltrán-Debón R; Alba V; Gatell JM; Vendrell J; Vidal F; Chacón MR
PLoS One; 2015; 10(12):e0144789. PubMed ID: 26658801
[TBL] [Abstract][Full Text] [Related]
17. Soluble CD163 and TWEAK in early pregnancy gestational diabetes and later glucose intolerance.
Dereke J; Nilsson J; Nilsson C; Strevens H; Landin-Olsson M; Hillman M
PLoS One; 2019; 14(5):e0216728. PubMed ID: 31071174
[TBL] [Abstract][Full Text] [Related]
18. Serum changes in sTWEAK and its scavenger receptor sCD163 in ultramarathon athletes running the 24-h race.
Benedetti S; Gemma Nasoni M; Palma F; Citarella R; Luchetti F
Cytokine; 2021 Jan; 137():155315. PubMed ID: 33011401
[TBL] [Abstract][Full Text] [Related]
19. Serum sTWEAK concentrations and risk of developing type 2 diabetes in a high cardiovascular risk population: a nested case-control study.
Díaz-López A; Chacón MR; Bulló M; Maymó-Masip E; Martínez-González MA; Estruch R; Vendrell J; Basora J; Díez-Espino J; Covas MI; Salas-Salvadó J
J Clin Endocrinol Metab; 2013 Aug; 98(8):3482-90. PubMed ID: 23760626
[TBL] [Abstract][Full Text] [Related]
20. TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis.
Dharmapatni AA; Smith MD; Crotti TN; Holding CA; Vincent C; Weedon HM; Zannettino AC; Zheng TS; Findlay DM; Atkins GJ; Haynes DR
Arthritis Res Ther; 2011 Mar; 13(2):R51. PubMed ID: 21435232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
